Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.
Wind your neck in about brexit singhie, it’s getting boring now ;)
Guessing you are the shorter who left that one star review then Wesley ;)
Nothing wrong with Ygen as a company , they have exciting products and if this deal goes through it will benefit NCYT and YGEN just not the majority of Ygen holders considering they bought at much higher prices.
Lynn Rees , has run YGEN into the ground . Have you looked at the shareprice now from where it was two years ago Neil ?
Have you also seen his average matches the offer price NCYT made to YGEN .
Dodgy as fook .
Lyn Rees - 85,371,235 @ average 0.521p - c. £445,000 invested
Good to finally see Novacyt do something with their cash . Novacyt and Ygen have worked together in the past . Just pray that lynn Rees the Welshman in charged of Ygen does NOT come with the deal .
That previous drop was uncalled for based on a groundbreaking new test , sales will come in time , hope everyone held their nerve .
It got five stars from me ;)
Order now and delivery date this Friday 23rd June . Ready to fly off the shelves , dont forget your five star review ;)
In my opinion Abbingdon are doing more than just distributing this test , more than likely they have been involved with the full process and design of the test . CDMO
. I would expect profit margins to be higher than £1 a test .
Also from the RNS .
Abingdon Health is a leading lateral flow contract development and manufacturing organisation ("CDMO") offering its services to an international customer base across industry sectors that include clinical, animal health, plant health, and environmental testing. Abingdon Health has the internal capabilities to take projects from initial concept through to routine and large-scale manufacturing; from "idea to commercial success."
The Company's CDMO division offers product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format. Abingdon Health aims to support the increase in need for rapid results across many industries and locations and produces lateral flow tests in areas such as infectious disease, clinical testing including companion diagnostics, animal health and environmental testing. Faster access to results allows for rapid decision making, targeted intervention and can support better outcomes.
Exclusive distributor .
Great news indeed .
The links muck shared certainly lead to announcements very soon .
Ready to launch very shortly then . I would imagine the SP to follow suit , especially when we hear about sales 🚀
Further distribution channels have been established in H1 2023 and early in H2, including a number of country-specific distribution agreements. The Company is aiming to add further self-tests, including those developed through its contract service activities, over the rest of FY 2023. Abingdon anticipates launching one of its CDMO customer's tests, the Salignostics Salistick™ saliva pregnancy test, on the Abingdon Simply Test™ site, in due course. We were pleased to see Salistick™ achieve Medicines and Healthcare products Regulatory Agency (MHRA) approval in March 2023 and will therefore be available for sale in the United Kingdom and we remain on target for an exclusive launch of Salistick™ on the Abingdon Simply Test™ website and on Amazon before the end of this financial year.
On further digging I also found this
Dr Chris Hand, Non-Executive Chairman of Abingdon Health plc, said: "Abingdon continues to build revenue across lateral flow development, technical transfer and manufacture. In addition, the Company's regulatory support gives customers an end to end offering of lateral flow expertise. The Abingdon Simply Test™ range brings this expertise and knowledge in lateral flow testing to the consumer and we will continue to expand our offering including unique products such as the Salistick™.
I can find details of our CDMO partnership with senzo.
Nothing in writing regarding a cdmo with salignostics out there to my knowledge but maybe news to the market regarding an agreement over and above distribution rights only may be worked on as we speak.
Abbingdon health can certainly provide large numbers of LFT to suit customer demand . I have seen this first hand with the abc123 covid test they produced at the height of the covid episode .
Do we have more details to the agreement that abbingdon have with the Israeli based company salistick ?
Are we merely a distributor or are we getting involved with manufacture also ?
Already up 9% on HL 😎
It is the 52week high of 15.25 p I refer to HD73 as stated on my HL screen . Anyway , it’s the most positive I have felt about a share for a while now.
All the best LTH and new investors .
This reminds me of the good old Novacyt days . My portfolio shot up beyond my belief , have followed Abingdon very closely since the abc123 covid antibody test .
I feel now is the time to be in this share .
And I am ;)
If we break 15.25p we are at a yearly high . Once we see some big order RNS coming through , this could do very well indeed.